This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
KANZHUN LIMITED Sponsored ADR (BZ) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
BZNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Is Kodak having a "Kodak moment?" 2 watchlist stocks.
by Mark Zinski
KODK and NRXS are worth watching for their growth.
KODKNegative Net Change NRXSNegative Net Change
basic-materials medical medical-devices small-cap
BTSG Gains More Than 54% YTD: Should You Buy, Hold or Sell?
by Indrajit Bandyopadhyay
BrightSpring Health Services has surged 54% YTD on specialty pharmacy, infusion and EBITDA growth, but premium valuation and policy headwinds remain.
BTSGPositive Net Change ADUSNegative Net Change OPCHNegative Net Change
medical medical-devices
CAH Gains More Than 29% in 4 Months: Will the Uptrend Continue?
by Indrajit Bandyopadhyay
Cardinal Health's 29% rally reflects stronger specialty growth, MSO expansion and higher-margin assets, but cost pressures could test the uptrend.
CAHNegative Net Change MCKNegative Net Change CORNegative Net Change
medical medical-devices
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery
by Zacks Equity Research
RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.
RVTYNegative Net Change WSTNegative Net Change GMEDNegative Net Change VCYTNegative Net Change
medical medical-devices
IceCure Secures China NMPA Approval for ProSense Cryoablation System
by Zacks Equity Research
ICCM's NMPA approval for ProSense opens China to commercialization, expanding its global regulatory footprint and long-term revenue opportunity.
ICCMNegative Net Change WSTNegative Net Change GMEDNegative Net Change VCYTNegative Net Change
medical medical-devices
New Strong Buy Stocks for September 11th
by Zacks Equity Research
RCMT, HCSG, BLMN, AGX and GMED have been added to the Zacks Rank #1 (Strong Buy) List on September 11, 2026.
BLMNPositive Net Change AGXPositive Net Change GMEDNegative Net Change HCSGNegative Net Change RCMTNegative Net Change
business-services construction medical-devices restaurants
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL benefits from high-tech growth, digital expansion, innovation and solid Q2 results, while cost fluctuations remain a key concern.
ECLNegative Net Change WSTNegative Net Change GMEDNegative Net Change VCYTNegative Net Change
medical medical-devices
COO Q3 Earnings Top Estimates, Revenues Miss on Destocking, Stock Down
by Zacks Equity Research
Cooper Companies' Q3 EPS beats estimates as expense controls offset softer revenues, while U.S. inventory cuts pressure CooperVision and weigh on shares.
COOPositive Net Change WSTNegative Net Change GMEDNegative Net Change VCYTNegative Net Change
earnings medical medical-devices
Do Options Traders Know Something About AtriCure Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
ATRCNegative Net Change
medical medical-devices